Obesity Trials in Chattanooga, United States
Conditions / Obesity / Chattanooga, United States
Obesity is a medical condition with active clinical research programs worldwide.
24 total trials for this combination
Showing top 10 of 24 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06077864 | A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | ACTIVE_NOT_RECRUITING | — |
| NCT05556512 | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01601704 | Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) | TERMINATED | PHASE3 |
| NCT00474630 | A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT04184622 | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | COMPLETED | PHASE3 |
| NCT02019264 | A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | COMPLETED | PHASE4 |
| NCT05514535 | A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | COMPLETED | PHASE3 |
| NCT06926842 | Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT00807768 | Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer | UNKNOWN | PHASE3 |
| NCT07533175 | AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | RECRUITING | — |